calcium, cyclic AMP, cystic kidney, hypercalciuria, kidney stones, kidney tubule, polycystic kidney disease, risk factors, polycystic kidney, autosomal dominant, tolvaptan, kidney calculi
dx.doi.org/10.2215/CJN.07610520, hdl.handle.net/1765/128750
Clinical Journal of the American Society of Nephrology
No Subscription.
Department of Internal Medicine

Zietse, R. (2020). ADPKD, tolvaptan, and nephrolithiasis risk. Clinical Journal of the American Society of Nephrology, 15(7), 923–925. doi:10.2215/CJN.07610520